The t4 Activation Domain of the Thyroid Hormone Receptor Is Required for Release of a Putative Corepressor(s) Necessary for Transcriptional Silencing
Open Access
- 1 January 1995
- journal article
- research article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 15 (1) , 76-86
- https://doi.org/10.1128/mcb.15.1.76
Abstract
The C terminus of nuclear hormone receptors is a complex structure that contains multiple functions. We are interested in the mechanism by which thyroid hormone converts its receptor from a transcriptional silencer to an activator of transcription. Both regulatory functions are localized in the ligand binding domain of this receptor superfamily member. In this study, we have identified and characterized several functional domains within the ligand binding domain of the human thyroid hormone receptor (TR beta) conferring transactivation. Interestingly, these domains are localized adjacent to hormone binding sites. One activation domain, designated tau 4, is only 17 amino acids in length and is localized at the extreme C terminus of TR. Deletion of six amino acids of tau 4 resulted in a receptor that could still bind hormone but acted as a constitutive silencer, indicating that tau 4 is required for both transactivation and relief of the silencing functions. In addition, we performed in vivo competition experiments, the results of which suggest that in the absence of tau 4 or hormone, TR is bound by a corepressor protein(s) and that one role of hormone is to release corepressor from the receptor. We propose a general model in which the role of hormone is to induce a conformational change in the receptor that subsequently affects the action of tau 4, leading to both relief of silencing and transcriptional activation.Keywords
This publication has 45 references indexed in Scilit:
- A novel cis element mediating ligand-independent activation by c-ErbA: Implications for hormonal regulationCell, 1993
- An arginine to histidine mutation in codon 311 of the C-erbA beta gene results in a mutant thyroid hormone receptor that does not mediate a dominant negative phenotype.Journal of Clinical Investigation, 1993
- Co-operative binding of the glucocorticoid receptor DNA binding domain is one of at least two mechanisms for synergismJournal of Molecular Biology, 1991
- Molecular Diagnosis and Characterization of Thyroid Hormone Resistance SyndromesThyroid®, 1991
- v-erbA oncogene activation entails the loss of hormone-dependent regulator activity of c-erbACell, 1990
- Transcriptional repression in eukaryotesTrends in Genetics, 1990
- A base mutation of the C-erbA beta thyroid hormone receptor in a kindred with generalized thyroid hormone resistance. Molecular heterogeneity in two other kindreds.Journal of Clinical Investigation, 1990
- A movable and regulable inactivation function within the steroid binding domain of the glucocorticoid receptorCell, 1988
- Negative effect of the transcriptional activator GAL4Nature, 1988
- Identification of a receptor for the morphogen retinoic acidNature, 1987